

- New enrolment
 Renewal

Enrol in Enliven[®]
 **1-833-423-0252**
 **1-877-936-2735**



Patient Information

Clear

First name
 Last name
 Female Male Date of birth / /
 (dd/mm/yyyy)
 Do you have health insurance coverage? Private Public Both

Contact Information

Preferred phone Alternate phone
 Preferred time to call Morning Afternoon Evening
 Preferred language
 Address
 City Province Postal code
 Email

Consent

By checking this box, I accept that representatives of McKesson Canada Corporation ("McKesson") and Bayshore Specialty Rx. Ltd. ("Bayshore"), acting on behalf of Amgen Canada Inc., may communicate with me via electronic means such as email and text message, for the purposes of providing me with information and updates relating to the Enliven Patient Support Program (the "Program"), including promotional materials, surveys and newsletters. I understand that communicating via electronic means may not be the most secure means of communication and as such, McKesson and/or Bayshore will not include sensitive health information in any electronic means of communication with me. Such electronic means of communications may, however, identify me as an individual registered with the Program. At any time, I will have the opportunity to opt-out from such electronic communications by contacting by phone at 1-877-936-2735 or via email at avsola@oneenliven.ca.

I HAVE READ, UNDERSTAND AND AGREE TO THE CONSENT TERMS ON THE REVERSE OF THIS FORM.

Patient signature **X**
 Date / /
 (dd/mm/yyyy)

Physician Information

Clear

Physician name
 Site # (if applicable)
 Phone Fax

Other information/office stamp

Prescribing Physician Section

Clear

Please ✓ and complete the required information

Diagnosis

- Rheumatoid arthritis (RA)
- Ankylosing spondylitis (AS)
- Crohn's disease (CD)
- Fistulising Crohn's disease (FCD)
- Ulcerative colitis (UC)
- Psoriatic arthritis (PsA)
- Plaque psoriasis (PsO)
- Other diagnosis

.....
 Patient weight
 Date of weight / /
 (dd/mm/yyyy)

Dose

mg/kg
 Exact dose (mg)

Frequency/Duration

Induction (weeks)
 0 2 6
AND/OR
 Maintenance
 Every weeks
 Repeat x or 52 weeks
 2 hr infusion
 Infuse AVSOLA[®] over no less than 2 hours.
 1 hr infusion
 RA patients who have tolerated three initial 2-hour infusions of AVSOLA[®] without any type of infusion reaction may receive subsequent infusions at the same dose over a period of not less than 1 hour.

For infusion reaction management, follow the suggested protocol.

Pretreatment orders

- No premedications required
- Diphenhydramine mg PO or IV
 15-30 min prior to infusion (max 50 mg)
- Acetaminophen mg PO 15-30 min prior to infusion
- Hydrocortisone mg IV 15-30 min prior to infusion
- Dimenhydrinate mg PO or IV 15-30 min prior to infusion
- Cetirizine mg PO 30 min prior to infusion
- Methylprednisolone
- Other

TB test

- Not required
- Positive result
- Negative result
- Results pending

CXR test

- Not required
- Completed
- Results pending

Patient to start AVSOLA[®]

- Immediately
- OR**
- Pending test results

Provincial formulary code

I authorize McKesson to be my designated agent to forward the prescription indicated above, by fax or other mode of delivery, to the Program specialty pharmacy or to the pharmacy chosen by the above named patient on my behalf. This prescription represents the original of the prescription drug order. The chosen pharmacy is the only intended recipient and there are no others. The original prescription has been invalidated and securely filed and it will not be transmitted elsewhere at another time.

Physician signature **X**
 Date / / Physician license #
 (dd/mm/yyyy)

SC=subcutaneous; TB=tuberculosis

Consent

By signing this form, I acknowledge that I have read and understand the information below and consent to the collection, use and disclosure of my personal information, including personal health information, by McKesson, Bayshore, Amgen and their authorized agents and service providers as explained. Furthermore, I acknowledge that the dispensing and delivery of my medication will be performed by a specialty pharmacy chosen by the *Enliven* Program unless I specify otherwise. I understand that I have the option to choose another pharmacy to dispense and deliver my medication. I further consent to being contacted from time to time by McKesson, Bayshore, Amgen or their authorized agents for the above-noted purposes.

The *Enliven* Program ("Program") is sponsored by Amgen Canada Inc. ("Amgen") and administered by McKesson, a third party service provider, on behalf of Amgen. Certain aspects of the Program are provided by Bayshore (e.g., administering, training or assisting in therapy). Other service providers may be appointed by Amgen to administer the Program from time to time. The personal information that you and/or your healthcare providers (including your doctor and pharmacy), insurers or payers provide to the Program, including your name, contact information, and prescription information, will be used to manage and administer the Program or provide Program services to you, including reimbursement assistance and administering, training or assisting in therapy (e.g., self-injection training), medication delivery, and provision of information about the Program to you.

Amgen has a legal obligation to report adverse drug events to various local and international health authorities and to monitor product complaints. Personal information provided to the Program may be (i) monitored by Amgen or its service providers for safety-related data and product complaints in order to ensure compliance with these legal reporting requirements, and (ii) reported to local or international health authorities. Amgen may contact you or your physician for additional information to fulfill its reporting obligations. Your personal information may be combined with the information of others who participate in the Program in order to generate aggregated data that does not contain identifying information ("Aggregated Data"). Aggregated Data may be used by Amgen and its service providers to improve and/or refine the Program to design and implement other patient programs and for research purposes including health economic studies and analysis, the identification of trends such as product utilization, adherence or outcomes (including treatment outcomes).

For these sole purposes, McKesson and Bayshore may on a confidential basis, collect your personal information and share it with your healthcare providers, insurers and/or other payers, Amgen and/or Amgen's agents and service providers (e.g., information technology providers). If, from time to time, another service provider is appointed by Amgen to administer the Program or provide Program services, your personal information will be transferred to this service provider to ensure the continuity of the Program services to you. Please note that Amgen and its service providers may store or process your personal information outside of Canada (including in the United States), where local laws may require the disclosure of personal information to governmental authorities under circumstances that are different than those that apply in Canada. In addition, your personal information may be used or disclosed to third parties when permitted or required by applicable laws, court orders or government regulations (collectively, "Applicable Laws").

Your personal information will be retained only for as long as is needed to fulfill the purposes for which it was collected and in order to comply with Applicable Laws. Industry standard safeguards will be used to protect the security of the personal information that is collected. You may contact the Program's Privacy Officer at any time to update or access your personal information, modify or withdraw your consent (in part or in full), express a privacy-related concern, or inquire about the privacy practices of the Program (including those related to foreign information processing). The Privacy Officer can be reached at privacycanada@amgen.com or Amgen Canada Inc., Attn: Chief Privacy Officer, 6775 Financial Drive, Suite 100, Mississauga, ON, L5N 0A4. Please note that if you modify or withdraw your consent, your ability to receive the Program services may be limited.

This document may contain private and confidential information and is intended only for the person(s) named on the reverse. If you are not a named addressee, you should not disseminate, distribute or copy this document. If you have received this document by mistake, please notify the sender immediately and then destroy this document. We thank you for your cooperation and assistance.

© 2020 Amgen Canada Inc. All rights reserved.
AVSOLA® is manufactured by Immunex Corporation and marketed by Amgen Canada Inc.
AVSOLA® is a registered trademark of Amgen Inc.
Enliven® is a registered trademark of Immunex Corporation, used with permission.



Enliven®

